Highbridge Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Highbridge Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14,224	Closed	-$2.74M	–	519
2018 Q3	$2.74M	Buy	+14,224	New	+$2.53M	0.07%	292
2018 Q1	–	Sell	-15,000	Closed	-$2.25M	–	1759
2017 Q4	$2.25M	Buy	+15,000	New	+$2.22M	0.04%	368
2017 Q3	–	Sell	-1,900	Closed	-$245K	–	1797
2017 Q2	$245K	Sell	1,900 -26,037	-93%	-$3.13M	﹤0.01%	1038
2017 Q1	$3.06M	Buy	27,937 +22,937	+459%	+$2.02M	0.04%	380
2016 Q4	$368K	Hold	5,000	–	–	0.01%	886
2016 Q3	$436K	Buy	+5,000	New	+$473K	0.01%	846
2016 Q2	–	Sell	-13,980	Closed	-$1.11M	–	1786
2016 Q1	$1.11M	Buy	+13,980	New	+$1.26M	0.02%	697
2015 Q4	–	Sell	-19,852	Closed	-$2.07M	–	1833
2015 Q3	$2.07M	Buy	+19,852	New	+$2.55M	0.03%	538
2015 Q2	–	Sell	-3,201	Closed	-$378K	–	1693
2015 Q1	$378K	Buy	+3,201	New	+$384K	0.01%	1048
2014 Q3	–	Sell	-88,359	Closed	-$8.37M	–	1385
2014 Q2	$8.37M	Buy	+88,359	New	+$6.2M	0.1%	205
2013 Q4	–	Sell	-123,181	Closed	-$9.34M	–	1347
2013 Q3	$9.34M	Buy	123,181 +30,844	+33%	+$2.45M	0.1%	242
2013 Q2	$7.39M	Buy	+92,337	New	+$6.8M	0.07%	268

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Highbridge Capital Management's VRTX Position: Q4 2018 in Review

Highbridge Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 14,224 shares — an estimated $2.74M sold.

Highbridge Capital Management first reported a position in VRTX in Q2 2013 and held it in 12 quarters. The position peaked at $9.34M in Q3 2013. 706 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

Highbridge Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Highbridge Capital Management sold 14,224 Vertex Pharmaceuticals shares in Q4 2018, an estimated $2.74M.
Highbridge Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Highbridge Capital Management's Vertex Pharmaceuticals position peaked at $9.34M in Q3 2013.
706 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on Highbridge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.